The cyclic peptide AF17121 is a libraryderived antagonist for human interleukin-5 receptor α (IL5Rα), and inhibits interleukin-5 (IL5) activity. Our previous results have demonstrated that the sixth arginine residue of the peptide is crucial for the inhibitory effect and several acidic residues in the Nand C-terminal regions also make a contribution though to a lesser extent. However, the recognition mechanism of the receptor has remained unresolved. In the present study, AF17121 was fused to thioredoxin by DNA recombinant techniques and examined for IL5Rα interaction by using a surface plasmon resonance biosensor method. Kinetic analysis reveals that the dissociation rate of the peptide-receptor complex is comparable to that of the cytokinereceptor complex. The fusion peptide competed with IL5 for both biological function and interaction with IL5Rα, indicating that the binding sites on the receptor are shared by AF17121 and IL5. In order to define the epitope residues for AF17121, we defined its binding footprint on IL5Rα using alanine-substitution of Asp 
Asthma is an incurable disease characterized by eosinophilic bronchial inflammation and tissue remodeling of the airway wall (1) . Human interleukin 5 (IL5) is a key cytokine which plays a critical role in the differentiation, proliferation, migration and activation of eosinophils and has been implicated in the pathogenesis of eosinophilassociated allergic inflammation such as asthma (2, 3) . Injection of IL5 increases eosinophil numbers in the blood, bone marrow, spleen and peritoneal cavities (4, 5) . This increase can be prevented by the passive administration of anti-IL5 or anti-IL5 receptor antibodies (5, 6) . One distinguishing characteristic of IL5 versus other cytokines is that IL5 functions selectively to activate eosinophils (7) . These data argue that IL5 plays a central role in the development of allergen-induced eosinophils and suggest that the ability to block IL5 activity evokes the potential for alternative treatment for asthma.
At the molecular level, IL5 leads to biological functions through recruitment of a cell surface receptor composed of two polypeptide chains, α and β (8) . The α chain is IL5-specific and is called IL5 receptor α (IL5Rα), while the β chain is shared with IL3 and GM-CSF (9, 10, 11) and is called common β chain (βc). Despite a high degree of amino acid sequence similarity of the α chains for IL5, IL3 and GM-CSF, their interaction with cognate cytokine is strictly specific and no cross-reactivity is found among these cytokines. Previous observations argue that receptor subunit recruitment occurs stepwise, with initial formation of IL5-IL5Rα complex required for βc binding to induce cytoplasmic signal transduction (12) . IL5Rα alone binds IL5 with an equilibrium dissociation constant of 0.8 nM when expressed in COS cells, and this binding affinity is increased only 1.5 fold when α and β chains are co-expressed (13) . Hence, receptor α provides most of the binding energy and specificity for IL5, while βc is primarily responsible for signaling events.
Putting these data together, the IL5-IL5Rα interaction can be seen as a promising target for designing specific inhibitors aimed at suppressing eosinophil-related inflammation. Extensive mutational analyses have identified recognition epitopes in both IL5 and IL5Rα, and the interaction can be envisioned by relating structure to function of these epitopes. IL5 is a symmetric homodimer in which each helical bundle domain is composed of three helices (A-C) from one chain and one (D) from the other (14) . The binding epitope on IL5 for IL5Rα is mapped on the structure, showing the importance of charged residues in helix B (His ) for IL5Rα binding (15, 16, 17) . For βc binding and signal transduction, Glu 13 in helix A is thought to be a key residue (17) . IL5Rα comprises three fibronectin-type III domains (D1, D2 and D3) in the extracellular region, and the membraneproximal pair D2 and D3 domains together constitute a cytokine recognition motif which generally can be recognized by a cytokine (18 ) of IL5Rα (19) . The homology-deduced IL5Rα structure indicates that the binding interface of the receptor α comprises a cluster of negatively-charged residues from D1 domain and a cluster of positively-charged residues from D2D3 domains. From these observations, we have proposed a hypothesis that a pair of charge complementary interfaces play an important role in specific interaction between IL5 and IL5Rα.
Peptide mimetic methodology has led to the discovery of specific inhibitors for the IL5-IL5Rα interaction. A potent disulfide-cyclized 18-mer peptide, AF17121, inhibits the binding of IL5 to IL5Rα and blocks IL5 dependent eosinophil activation (20) . Recently, using mutational analysis of AF17121, our group has found that the sixth arginine residue plays a crucial role for the antagonist effect, and N/Cterminal acidic residues make a lesser contribution (21) . Although AF17121 proved to be a specific antagonist of IL5Rα showing the importance of its charged clusters for its antagonism, the binding mechanism for IL5Rα, including the binding epitopes on the receptor, has remained incomplete. The purpose of the present study was to elucidate these mechanistic features of AF17121 by means of kinetic analysis and site-directed mutagenesis with IL5Rα. To enhance the solubility and binding signal of the peptide in surface plasmon resonance (SPR) assays, we employed a recombinant system to fuse the peptide to a highly-soluble protein, thioredoxin. We used the thioredoxin-fused AF17121 for kinetic interaction analysis with soluble IL5Rα (sIL5Rα, extracellular domain of IL5Rα; ref. 22) as well as for biological inhibition assays. Alaninesubstitution of the two half cystine residues in AF17121 completely impaired its binding to IL5 receptor α and its corresponding inhibitory action on cells. Furthermore, we used SPR binding analysis of sIL5Rα alanine-scanning mutational variants to explore the functional impact of each amino acid on the kinetic interaction of the receptor with AF17121. In spite of the small size of the peptide, marked effects on the interaction were observed in the entire IL5 receptor α footprint for IL5. The revealed mechanism of cytokine mimicry simplifies the complexity of the IL5-receptor interaction, and evokes several models for how IL5 induces activation of the multi-subunit receptor system.
MATERIALS AND METHODS
Materials -Human IL5 protein and soluble human IL5Rα used in the present work were produced and purified as previously described (12) . Mouse IL3 protein was purchased from Sigma-Aldrich (St. Louis, MO). The anti human IL5Rα monoclonal antibody α16 was a generous gift from Dr. J. Tavernier (University of Ghent, Ghent, Belgium). All the enzymes were purchased from New England Biolabs (Beverly, MA). Mouse BaF3 cell line was purchased from German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). All the oligo DNA primers, Drosophila Schneider 2 (S2) cells, cell culture media, L-glutamine solution (200 mM) and RPMI 1640 medium were purchased from Invitrogen (Carlsbad, CA). For surface plasmon resonance measurements, the sensor chip CM5, surfactant P20, N-ethyl-N-(3-dimethylaminopropyl)carbodiimide (EDC), Nhydroxysuccinimide (NHS), 1 M ethanolamine (pH 8.5), and 10 mM glycine-HCl (pH 1.5 and 2.0) were purchased from Biacore (Piscataway, NJ).
Construction of Expression Plasmids for
Thioredoxin-fused AF17121 -The DNA sequence of AF17121 peptide (Fig. 1A) was designed by using the E. coli K12 codon usage tabulated from GenBank (CUTG, ref. 23). The oligonucleotide primers used for this study are as follows: 5'-p-CATGGTTGACGAATGCTGGCGTATCATC GCTTCCCACACCTGGTTCTGCGCTGAAGA ATGAA-3' and 5'-p-AGCTTTCATTCTTCAGCGCAGAACCAGGT GTGGGAAGCGATGATACGCCAGCATTCG TCACC-3'. Annealing was achieved with 10 nmole of sense and antisense oligonucleotides in 100 µL of annealing buffer (10 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 7.5). The reaction mixture was incubated at 95°C for 5 min and at 65°C for 10 min, and then was allowed to cool slowly at room temperature for 1 hour. The double-stranded fragment was then ligated to an expression vector pET-32b (Novagen) which had been digested with NcoI and HindIII. The resulting plasmid was named pTRXaf17. In this construct, the gene for thioredoxin, hexahistidine, S-tag peptide, enterokinase cleavage site and AF17121 sequences were placed behind the T7 promoter. The amino acid sequence of the final product (denoted trx-AF17121) is shown in Figure 1B . For the cysteine-to-alanine variant (denoted trx-AF17121[AA]) at positions 4 and 15 (numbering as AF17121 peptide), mutations were introduced into pTRXaf17 with a QuikChange site-directed mutagenesis kit (Stratagene) using the synthetic oligo DNA 5'-GTTGACGAAGCCTGGCGTATCATCGCTTC CCACACCTGGTTCGCCGCTGAAGAA-3' as a forward primer and its reverse complementary sequence as a reverse primer. Presence of the desired mutations was verified by DNA sequencing.
Expression and Purification of Fusion Peptides in E. coli -For production of trx-AF17121, the plasmid pTRXaf17 was transformed into the host strain BL21-CodonPlus (DE3)-RIL (Stratagene). The transformed cells were grown in 1 L LB medium at 37°C and expression was initiated by addition of 1 mM isopropyl-β-D -(-)-thiogalactopyranoside at a cell growth of 0.8 OD (600 nm). After 3 h cells were harvested and frozen at -20°C. The frozen cell paste was suspended in 10 mL lysis buffer (100 mM TrisHCl, pH 8.0, 100 mM NaCl, and 1 mM phenylmethanesulfonyl fluoride) per 1 g wet cells, followed by sonication for 20 min on ice. Insoluble material was removed by centrifugation at 20,000 ×g for 30 min at 4°C. The supernatant was then loaded onto a HiTrap Chelating HP column (Amersham Biosciences) pre-equilibrated with lysis buffer. Any nonspecific binding proteins were washed away with buffer A (50 mM Tris-HC1, pH 7.4, 25 mM imidazole, 300 mM NaCl), and the fusion peptide was eluted with a linear gradient from buffer A to buffer B (50 mM Tris-HC1, pH 7.4, 300 mM imidazole). The protein fraction was diluted five times in the redox buffer (1 mM reduced glutathione, 10 mM oxidized glutathione, 100 mM Tris-HCl, pH 8.5) and stirred to allow disulfide bond formation (24 h, 4°C). The protein solution was dialyzed against buffer C (20 mM Tris-HC1, pH 8.0) and then loaded onto a HiTrap Q HP column (Amersham Biosciences) pre-equilibrated with buffer C. The protein was eluted with a linear gradient from 0 to 1 M NaCl in buffer C. The fused protein was located in the 0.1-0.2 M NaCl fraction. The buffer of the purified protein fraction was exchanged to PBS buffer (1 mM KH 2 PO 4 , 10 mM Na 2 HPO 4 , 137 mM NaCl, 2.7 mM KCl, pH 7.4) using a HiPrep 26/10 desalting column (Amersham Biosciences) and the resulting protein solution was stored below -80°C. The purified protein was analyzed by SDS-PAGE (4-20% linear gradient gel, Bio-Rad Laboratories). The Cys mutant trx-AF17121[AA] and thioredoxin protein were produced and purified in the same manner as trx-AF17121, except for the oxidation process. The original expression vector pET-32b was used for production of thioredoxin. (24) .
Characterization of Fusion Peptides
The amount of free cysteine residues in trx-AF17121 and trx-AF17121[AA] was measured with DTNB (Ellman's reagent; ref. 25) . Protein (0.3 µM) and DTNB (1 mM) were incubated for 20 min at room temperature in 100 mM sodium phosphate buffer (pH 7.3) including 1 mM EDTA. The absorbance at 412 nm was measured and the moles of sulfhydryl group were determined using the extinction coefficient of oxidized DTNB (ε 412 = 13,600 M -1 cm -1 ). Reactivity of DTNB with the buffer was subtracted from the results obtained. The number of sulfhydryl groups per molecule was then corrected using a standard curve obtained with reduced glutathione.
The apparent molecular weight (MW) and oligomeric state of trx-AF17121 proteins were evaluated by using an HPLC system with a 7.8 × 300 mm BioSep-SEC-S-2000 size exclusion analytical column (Phenomenex) preequilibrated with PBS buffer. The column was calibrated with standards of known molecular mass (Amersham Biosciences). Linear regression, of log 10 (MW) versus elution volume of the standard, was used to extrapolate the apparent molecular weights of the fusion peptides.
S2 Cell Expression of IL5Rα and its
Mutational Variants -Soluble IL5Rα (sIL5Rα) and its mutational variants (D55A, D56A, E58A, K186A, R188A and R297A) were transiently expressed in Drosophila S2 cells and secreted into serum-free medium as previously reported (19) . Cell-free supernatant was collected after 2 days and stored at -20°C for the following binding analysis.
SPR Biosensor
Binding Analysis -The kinetic interaction assay was carried out using an SPR biosensor, Biacore 3000 (Biacore, Uppsala, Sweden). All the experiments were conducted at 25°C in PBS buffer containing 0.005% P20.
Non-covalent immobilization of IL5Ra and binding assay of the fusion peptides -A conformation-sensitive anti-IL5Rα monoclonal antibody α16 (26) was covalently immobilized on a CM5 sensor chip and sIL5Rα was captured by the antibody, as described previously (19) . Various concentrations of trx-AF17121 or trx-AF17121[AA] was passed over the antibodycaptured sIL5Rα surface. To examine the interaction of sIL5Rα mutational variants with trx-AF17121, each receptor mutant was captured to a level of almost 200 resonance unit (RU).
Covalent immobilization of fusion peptides and binding assay of IL5Rα. -Immobilization of trx-AF17121 and trx-AF17121[AA] on a CM5 sensor chip was carried out by the amine coupling method (BIAapplication handbook; Biacore). Briefly, ca 10 µM protein solution was diluted 50 times in 10 mM acetate (pH 4.0) and injected onto a biosensor surface which had been pre-activated with a 20 µL injection of 1:1 mixture of 200 mM EDC and 50 mM NHS, followed by the injection of 1 M ethanolamineHCl (pH 8.5). The amounts of immobilization were around 200 RU. The real-time interaction was measured by injecting purified sIL5Rα onto these surfaces. The thioredoxin-coupled surface was used as reference surface to correct for instrument and buffer artifacts. To regenerate chip surfaces, bound proteins were removed from the surfaces by an injection of 10 mM glycine-HCl, pH 2.0 after each cycle. All the procedures were automated to create repetitive cycles of injection of various concentrations of sIL5Rα (flow rate; 50 µL/min), and the regeneration buffer (flow rate; 100 µL/min).
Data analysis -Nonlinear least-squares analysis was used to calculate the association and dissociation rate constants (k on and k off , respectively). Prior to the calculation, the binding data were corrected for non-specific interaction by subtracting the reference surface data from the reaction surface data, and further corrected for buffer effect by subtracting the signal due to buffer injections from those of protein sample injections (double referencing; ref. 27 ). The interaction curves thus obtained were globally fit using a model for Langmuir 1:1 binding (BIAevaluation software, Biacore). Individual kinetic parameters were obtained from at least three separate experiments. The equilibrium dissociation constant (K d ) was calculated as
Control experiments for mass transfer effect on biosensor -To assess the effect of amount of immobilization on the apparent reaction rate constants, different injection times were used to vary the level of immobilization of sIL5Rα. Various amounts of sIL5Rα were captured by α16 on the surface, and trx-AF17121 solutions at a concentration of 40 nM were passed over each amount of immobilized sIL5Rα. The binding data were collected at flow rate 10 µL/min. The effect of flow rate on the apparent reaction rate constants was also assessed. The amount of sIL5Rα captured by α16 on the sensor chip was fixed at 130 RU, and trx-AF17121 solutions at a concentration of 40 nM were passed over the immobilized sIL5Rα. The binding data were collected at flow rates 10, 20, 40 and 80 µL/min.
SPR Competition Assay -The effectiveness of trx-AF17121 and trx-AF17121
[AA] to inhibit the IL5-IL5Rα interaction was evaluated by two types of competition experiments. The first set of experiments measured the ability of the fusion peptides to compete with IL5 binding to sIL5Rα as described previously (21) . For this competition assay, 4 nM sIL5Rα in the absence and the presence of the different concentrations of trx-AF17121 or trx-AF17121[AA] was passed over the IL5-captured surface (~200 RU). The second sets of experiments measured the ability of IL5 to compete with trx-AF17121 binding to sIL5Rα. In this experiment, trx-AF17121 was directly immobilized on a CM5 sensor surface as described above. Over this surface, 80 nM sIL5Rα was passed in the absence and presence of different concentrations of IL5 or trx-AF17121. The concentration of sIL5Rα in each experiment was set close to the K d value of the interaction of IL5Rα with IL5 or AF17121 (see below).
Data analysis -The maximum binding response (R max ) of the IL5-IL5Rα interaction under the influence of trx-AF17121 was calculated by globally fitting the association and dissociation phases of sensorgrams. Fits were to a 1:1 Langmuir model. Data analysis was conducted using the BIAevaluation program and Microsoft Excel. Inhibitory effects of the peptides, resulting in decreases in the R max values, were expressed as ∆RU eq , maximum inhibitory effects as ∆RU max , and peptide concentration as C, IC 50 values can be calculated from the following equation: 
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A plot of ∆RU eq /C against ∆RU eq at different peptide concentrations thus gave a straight line from which the IC 50 value was obtained.
Biological Assay -The assay was carried out using human erythroleukemia IL5-dependent cell line, TF1.28 and the mouse pro B lymphocyte IL3-dependent cell line, BaF3. Both TF1.28 and BaF3 cells were cultured in RPMI 1640 medium 10% FCS (Hyclone) supplemented with 10 nM human IL5 or 10 nM mouse IL3, respectively. Cell proliferation was measured using the tetrazoluim salt, WST-1 (4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio-1,3-benzene disulfonate, Roche Diagnostics). Plates with 96-wells were seeded with 5000 cells/well and incubated for 48 h (37°C, 5% CO 2 ) in the presence of 10 pM IL5 for the TF1.28, or 2.5 pM IL3 for the BaF3 cells with different concentrations of trx-AF17121 or trx-AF17121 [AA] . Following the 48 h incubation, 10 µL of soluble WST-1 was added to each well and incubated for 4 h (37°C). The plate was then read using a microplate reader at an absorbance of 450 nm with a 650 nm reference. Individual values were obtained from three experiments and the average values were analyzed using Prism software (Graph pad).
RESULTS
Design, Production and Characterization of Thioredoxin-fused AF17121 -As previously reported, AF17121 showed inhibitory effects on IL5 function and proved to be a promising lead for rational drug design (20, 21) . To elucidate the detailed mechanism of these effects, we first carried out an interaction assay of AF17121 synthetic peptide by using surface plasmon resonance (SPR) based technology. Since the binding signal in SPR biosensor analysis is proportional to the molecular mass of interacting species, it is often difficult to detect signals from low molecular weight peptides. Enhancing the binding signal can be achieved by increasing the amounts of immobilized protein. However, large amounts of immobilization often cause non-ideal effects such as mass transfer, rebinding, crowding and steric hindrance which may result in deviations from ideal binding data. In the case of AF17121 synthetic peptide, we could not observe its binding signal on the surface immobilized with a relevant amount of sIL5Rα (data not shown). To overcome the signal sensitivity limitation and eliminate these artifacts in SPR-based biosensors, we used a recombinant system to fuse the peptide (2 kDa) to thioredoxin. Since the final product has a molecular weight of 19 kDa, ten-fold enhancement of the binding signal can be expected. The reason we chose thioredoxin as a fusion partner is that thioredoxin is known to be overexpressed in bacteria without formation of inclusion bodies (28) . Thioredoxin also is advantageous for biophysical experiments because the protein is stable to heat and highly soluble.
We designed and produced a fusion peptide which consists of thioredoxin, hexahistidine, S-tag peptide, and AF17121 from N-to C-terminus (Fig. 1B) . To investigate the importance of the disulfide bonded cyclic structure in AF17121, we also designed a mutant trx-AF17121[AA] in which Cys 4 and Cys 15 were replaced with alanine by site-directed mutagenesis. The recombinant protein was expressed in high yield, and the content of the protein was estimated to be half of the total cell protein judging from SDS-PAGE (Fig. 1C) . After sonication and ultracentrifugation, the fusion protein was present not in the inclusion body but rather in the soluble fraction. After purification by standard Ni-chelating affinity column chromatography, oxidation of free cysteine and disulfide bond formation was carried out using a redox equilibrium system. Oxidized trx-AF17121 contained no detectable free sulfhydryl group as judged using Ellman's reagent, confirming complete disulfide bond formation of the AF17121 domain ( Table I) . Even though we used a low concentration of protein solution during the oxidation process, bands of intermolecular disulfide bond formation were detected in non-reducing SDS-PAGE. The reaction mixture was further purified by anion exchange column chromatography, providing a yield of ca 5 mg of the purified monomeric trx-AF17121 from 1 L of culture. The purity of the protein was assessed by SDS-PAGE, revealing a single band between 20.7 and 28.8 kDa (Fig.  1C) . The same molecular mass was observed in non-reducing SDS-PAGE, demonstrating that there was no detectable intermolecular disulfide bond formation (data not shown). The final products were characterized by analytical HPLC for purity (usually > 95%) and MALDI MS for molecular weight, as shown in Table I .
The oligomeric states of trx-AF17121 and trx-AF17121[AA] were evaluated by size exclusion chromatography. The fusion proteins were loaded onto a gel filtration column at a concentration of 10 µM, and each of them eluted close to the volume observed for chymotrypsinogen (standard marker, molecular weight 25 kDa). The apparent molecular weights of the fusion proteins were slightly higher than expected ( Table I) . This may be because the long linker between thioredoxin and AF17121 peptide makes its size appear more extended than globular proteins. Nevertheless, the data confirm that both trx-AF17121 and trx-AF17121[AA] exist in a monomeric state and do not self-associate as oligomers in solution. The thioredoxin thus proved helpful to enhance solubility of the peptides, because mutation of cysteine residues in AF17121 synthetic peptide caused aggregation over a concentration of 10 µM (data not shown).
Kinetic Interaction of the Fusion Peptides with
IL5Rα -It has been shown previously that AF17121 synthetic peptide inhibits the IL5-IL5Rα interaction by binding to IL5Rα (20) . Here, to validate the direct binding of AF17121 to IL5Rα and the binding stoichiometry, we employed the sandwich SPR-based binding assay which has been established for cytokinereceptor interaction by our group (15, 19) . Figure 2A shows whole real-time sensorgrams of sIL5Rα capture and the subsequent complex formation of IL5 or trx-AF17121 on the biosensor surface. Under saturating concentrations, the bound trx-AF17121 produced a signal with nearly half the intensity of the bound IL5. In contrast, no direct interaction between trx-AF17121 and IL5 was observed (data not shown). Because the biosensor signal is proportional to the mass, it is possible to estimate the binding stoichiometry of trx-AF17121 based on its mass difference with IL5. When 230 RU sIL5Rα was captured on the surface ( Fig. 2A) , the R max value of IL5 (glycosylated form, 34 kDa) was 105 RU and that of trx-AF17121 (19 kDa) was 49 RU. Using IL5 as a reference, the calculated molar ratio of IL5 and trx-AF17121 was 1 versus 0.86. Since IL5 has been demonstrated to interact with IL5Rα with a 1:1 stoichiometry (29), this finding demonstrates that a 1:1 complex is formed between AF17121 and IL5Rα, Prior to the determination of the kinetic constants, it is important to determine the optimal experimental conditions to eliminate artifacts in SPR biosensor assays. In particular, mass transfer effect can be a major artifact when association rate is fast or a large amount of immobilization is required (30) . Indeed, the binding of IL5 to sIL5Rα was compromised by mass transfer effect even when using as low a level of immobilization as possible (19) . The presence of mass transfer effect is easily detected, as the binding signal will be dependent on the level of immobilization. Without mass transfer effect, binding sensorgrams generated from various amounts of immobilized protein should be able to be superimposed by normalizing the R max value. To assess the effect of immobilization level on the kinetics, 40 nM solutions of trx-AF17121 were injected onto various amounts of immobilized sIL5Rα. No significant difference of the binding signals was observed at varying levels of immobilization (Fig. 2B) . We further examined the presence of mass transfer effect by measuring the association rates with a flow rate in the range 10 to 80 µL/min. Figure 2C shows a slight increase in the association rate with increasing flow rate, indicative of mass transfer effect at slower flow rates. Since the flow rates of 40 and 80 µL/min did not alter the measured association rates, further kinetic experiments were performed at a flow rate of 50 µL/min.
We applied these conditions to study the interaction between trx-AF17121 and sIL5Rα. We prepared the biosensor surfaces immobilized with either sIL5Rα or trx-AF17121, and measured the binding of trx-AF17121 (Fig. 3A) and sIL5Rα (Fig. 3D) , respectively. The global fitting of the data sets showed no deviation from a simple 1:1 binding model (Fig. 3B, E) , confirming the 1:1 binding stoichiometry of the AF17121-IL5Rα complex. The binding characteristics were different depending on which component was immobilized ( Table II) . The association rate constants were three times faster when sIL5Rα was immobilized than when trx-AF17121 was immobilized, while the dissociation rate constants were almost the same for both types of immobilized surfaces. These differences can be seen visually by comparison of the sensorgrams (Fig. 3B, E) . Due to this difference of association rate constants, the binding affinity was about three-fold higher when sIL5Rα was immobilized. No binding of sIL5Rα was observed in the control surface immobilized with thioredoxin, showing that the observed binding ability of trx-AF17121 is basically due to the peptide moiety. Therefore, we could exclude the possibility that a cooperative effect of thioredoxin could help AF17121 to bind to the immobilized sIL5Rα. One possible explanation is that the different configurations of immobilization lead to different levels of accessibility to immobilized components. Since sIL5Rα is immobilized via α16 antibody, the antibody might play a role as a spacer and make a more barrier-free environment for the interacting components in the mobile phase.
In order to investigate the importance of cyclic constraints for the high affinity binding of AF17121, we also prepared a linear version of trx-AF17121 replacing Cys 4 and Cys 15 with alanine (numbering as AF17121 peptide). This mutation on the protein was confirmed by means of mass spectroscopy ( Table I ). Figure 3C shows the sensorgrams of trx-AF17121[AA] injection onto the sIL5Rα-captured surface. In contrast to the high-affinity binding of trx-AF17121, the cysteine-to-alanine variant was found to lose the binding activity for sIL5Rα. This loss of activity is not attributable to the aggregation of trx-AF17121[AA], because oligomers were not seen at the concentrations (10 µM) used by gel filtration analysis ( Table I) . The failure of receptor binding was further confirmed by another configuration of the binding assay, in which trx-AF17121[AA] was immobilized onto a sensor surface and the surface was challenged with sIL5Rα (Fig 3D) . Since sIL5Rα is very soluble and exists as a monomer even at high concentrations up to 10 µM (29), this configuration seems to be least affected by aggregation, if at all. With the trx-AF17121[AA]-coupled surface, no complex formation of sIL5Rα was observed as shown in Figure 3F . These results demonstrate that the disulfide bond bridge of AF1721 is crucial for binding to IL5Rα.
Competitive Inhibition of the Fusion PeptideTwo types of SPR-based experiments were performed to examine the inhibition of IL5-IL5Rα interaction by AF17121. In the first experiment, IL5 was captured by anti-IL5 monoclonal antibody 4A6 which was immobilized on the biosensor chip (Fig 4A) . Soluble IL5Rα was pre-incubated (1 hr) with different concentrations of the peptides and then injected onto the IL5-captured surface. Trx-AF17121 showed inhibition of receptor α chain binding to IL5 in a dose-dependent manner (Fig  4B) , although inhibition was incomplete as previously found in the competition assay for AF17121 synthetic peptide (21) . As expected, trx-AF17121[AA] did not inhibit the IL5-IL5Rα interaction at concentrations of trx-AF17121[AA] up to 12 µM (Fig 4C) . This finding demonstrates the considerable importance of the disulfide bond bridge of AF17121 for its inhibitory activity. The inhibitory effect of trx-AF17121 was quantitated from the decrease of the R max value depending on the peptide concentrations. A plot of ∆RU eq /C against ∆RU eq at different peptide concentrations gave an IC 50 value of 18 nM as the inverse of slope (see Materials and Methods).
In the second experiment, sIL5Rα was pre-incubated (1 hr) with different concentrations of IL5 and then injected onto the trx-AF17121-coupled surface (Fig 4D) . IL5 showed concentration-dependent inhibition for the peptide-receptor interaction and achieved complete inhibition with a concentration of 128 nM or higher (Fig 4E) . The IC 50 value of IL5 versus immobilized trx-AF17121 was 130 nM. To further omit the possibility that the incompleteness of inhibition observed in the first experiment is due to aggregation of the peptide, we tested the auto-inhibition of trx-AF17121 for the receptor binding. Mixtures of sIL5Rα and different concentrations of trx-AF17121 were injected onto the trx-AF17121-coupled surface (Fig 4F) . The soluble trx-AF17121 was found to compete with the immobilized trx-AF17121 binding to sIL5Rα, making it unlikely that a trivial reason such as trx-AF17121 aggregation could explain the incomplete inhibition shown in Figure 4B .
Specificity in Biological Action of the Fusion
Peptide -The ability of trx-AF17121 to block IL5 function was examined by cell proliferation using IL5-dependent TF1.28 cells. In the absence of the inhibitor, IL5 exhibited a dosedependent proliferation of TF1.28 cells with an ED 50 value of 6.6 pM (Fig. 5A) . Therefore, the inhibition assay was carried out with 10 pM IL5 which induces around 50% proliferation of the cells. Trx-AF17121 exhibited a dose-dependent inhibition of proliferation, while trx-AF17121[AA] showed no significant inhibitory activity. The IC 50 value for trx-AF17121 (560 nM) was similar to the value previously determined for AF17121 synthetic peptide (21) , suggesting that the physical size of thioredoxin makes no steric contribution to the inhibitory effect of AF17121. We found a more than tenfold difference between this biological IC 50 value and the IC 50 value (18 nM) determined from the binding assay above. This difference in the potency of inhibition between in vivo and in vitro assays may be attributed to the difference between the ED 50 value (6.6 pM) and the K d value (3 nM) for IL5-IL5Rα interaction. To verify whether the inhibition of cell proliferation was dependent specifically on the inhibition of the IL5-IL5Rα interaction, we examined whether trx-AF17121 could block the proliferation of IL3-dependent BaF3 cells. IL3 exhibited a dose-dependent proliferation of BaF3 cells with an ED 50 of around 4.7 pM (Fig. 5B) . This proliferation of BaF3 cells was unaltered in the presence of trx-AF17121 (Fig. 5B) . This argues that the inhibitory action of AF17121 is specific in the IL5-dependent TF1.28 cell proliferation assay. , are involved in high-affinity binding to IL5. Because trx-AF17121 competed with IL5 binding to the receptor as found in the previous section, we assumed that the binding sites for the receptor can be partially or fully overlapped between IL5 and AF17121. In the present study, therefore we chose these key residues for alanine site-directed mutagenesis to define the binding epitope for AF17121. We used the sandwich SPR biosensor method, in which each mutational variant of sIL5Rα is captured by the antibody α16, providing an oriented receptor surface to be challenged with trx-AF17121 for the quantitative binding analyses (Fig. 3A) . Mutants D55A, R188A and R297A showed impaired binding to trx-AF17121 (Fig. 6) . It is noteworthy that the sensitive residues are in all the fibronectin-type III domains of IL5Rα, namely, in D1 (D55A), D2 (R188A) and D3 domains (R297A). In contrast, mutants D56A, E58A and K186A showed a similar binding affinity to that of wild type receptor. For comparison, the relative values for k on , k off and K d are listed in Table III . We found that such mutations as D56A and E58A caused a slight increase in the binding affinity (less than 2-fold decrease in the K d ). As shown in Table III , these decreased K d values were attributed to increases in the k on and decreases in the k off . Of note, Asp 56 and Glu 58 are negatively-charged residues located in D1 domain of IL5Rα. Since AF17121 is a highly acidic peptide (calculated isoelectric point; pI = 4.6), this fractionally increased binding affinity may reflect the reduction of electrostatic repulsion between these negatively-charged residues of IL5Rα and some negatively-charged residues of AF17121 peptide.
Analysis of Binding Epitope on IL5Rα
DISCUSSION
AF17121 Utilizes Receptor Epitope -The cyclic
peptide AF17121 is a library-derived antagonist for human interleukin-5 receptor α, and blocks IL5 function (20) . The goals of this study were to provide insight into the receptor recognition mechanism of AF17121 and to propose a basis for the rational design of potent drugs for human asthma. Our previous results have postulated that the antagonist peptide might mimic the charge distribution of a receptor binding epitope 88 
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92 in IL5 (21) , which prompted us to investigate whether AF17121 binds to IL5Rα in the same manner as IL5. In the present study, we obtained a high-activity recombinant construction of AF17121, namely trx-AF17121, and demonstrated its effectiveness in binding to sIL5Rα in several biosensor assay configurations. This formed the basis for mapping receptor α epitope usage.
Using the recombinant trx-AF17121 fusion enabled facile binding analysis to both surface-captured as well as freely soluble sIL5Rα by means of an SPR based technique (Fig. 3) . By measuring association and dissociation rates, kinetic analysis can provide deeper understanding of interaction dynamics. The receptor interaction of trx-AF17121 showed thirty times slower association rate and two times slower dissociation rate than those of IL5, leading to fifteen times weaker binding affinity (Table II) . Association rate can be affected by such factors as electrostatic steering forces and conformational rearrangements for the final rigid complex. The latter could explain the slow association rate of the peptide, since the effective conformational rearrangement could play a key role in the formation of IL5-IL5Rα complex (19, 29) . The measured dissociation rate for the peptide-receptor complex was comparable to that for the cytokine-receptor complex. AF17121 could achieve high affinity binding due to decreased dissociation. This is more likely because the peptide was affinitymatured by several rounds of selection (20) . Since the slow dissociation rate is ascribed to the stability of the final complex, this observation indicates that AF17121 can employ similar interaction mechanisms to IL5. Receptor binding was completely eliminated by linearizing the cyclic conformation of the peptide (Fig. 3C, F) , suggesting that the full antagonism of AF17121 requires not only a composition of the binding residues, which are the sixth arginine residues and a cluster of N-/C-terminal acidic residues, but also a proper spatial alignment of these residues. Although we cannot exclude the possibility that disulfide bond bridge of AF17121 could be involved in the direct interaction with the receptor, the findings of the importance of charge complementary interaction (see below) support the idea that the disulfide bond is critical for stabilizing a functional conformation rather than for direct interaction.
Next, we addressed the question of whether AF17121 and IL5 compete for the same binding site on IL5Rα. To answer this question, we examined the inhibitory effect of trx-AF17121 on sIL5Rα binding to both the surface-coupled IL5 (Fig. 4A) and freely soluble IL5 (Fig. 4D) . The latter configuration showed the complete inhibition of AF17121-IL5Rα interaction by IL5 (Fig. 4E) , indicating that AF17121 is more likely to compete with IL5 for the same binding sites on the receptor. Interestingly, IL5 inhibited sIL5Rα binding to the surface-coupled trx-AF17121 with a concentration of half maximum inhibition (IC 50 = 130 nM) which is a similar value to the affinity constant between sIL5Rα and the surface-coupled trx-AF17121 (K d = 158 nM, Table II ). As we observed previously (21) , the maximum inhibitory effect of AF17121 did not exceed 60% in the experimental configuration as shown in Figure 4A , although trx-AF17121 inhibited the IL5-IL5Rα interaction with an IC 50 of 18 nM corresponding to its affinity constant (K d = 45 nM, Table II ). The incomplete inhibition may occur because the association rate of AF17121 is not fast enough to completely suppress IL5 binding to immobilized sIL5Rα. Another possibility is that IL5 still can interact with the preformed AF17121-IL5Rα complex. This latter possibility is consistent with the observation that AF17121 binding requires only a subset of the IL5Rα residues involved in IL5 binding (Fig. 6) . In this case, the peptide might not block all of the IL5 binding epitope of IL5Rα.
Our previous study pointed to the presence of a predominantly negatively-charged IL5-recognition epitope in the N-terminal region of IL5 receptor α and a predominantly positively-charged recognition epitope in the Cterminal region (19 (Fig. 7) . In the present study, we explored the functional impact of these amino acid residues on the kinetic interaction of the receptor with AF17121. Despite the small size of the peptide, marked effects on the interaction were mapped into all three domains of IL5Rα, similar to IL5, namely, Asp 55 in D1 domain, Arg 188 in D2 domain, and Arg 297 in D3 domain ( Fig. 6 and 7) . It is well known that the overall β-sandwich structures of receptors are very similar to each other in class I cytokine receptor family, and large variations are found in loops between the β-strands (31). Availability of the crystal structure of erythropoietin (EPO)-erythropoietin receptor (EPOR) complex (32) and EPO mimetic peptide 1 (EMP1)-EPOR complex (33) enabled us to compare the receptor recognition mechanism by AF17121 and IL5. Since the D2D3 tandem domain is a cytokine recognition motif (18) and similar to EPOR, it is interesting to look at the EPOR residues at the equivalent positions of Arg 188 and Arg
297
. They are Phe 93 and Phe 205 respectively, which are the major residues creating the hydrophobic interaction surface for both EPO and EMP1. While contact of EPO and its mimetic peptide are dominated by hydrophobic residues, that of IL5 and AF17121 are dominated by charged residues. and Arg 188 of IL5Rα are the critical residues for high-affinity binding to IL5 and are responsible for fast association of the IL5-IL5Rα interaction (19) . Hence, we conclude that AF17121 binds to the region which is mostly overlapped by the IL5 binding epitope on the receptor and targets the most critical binding residues for the cytokine.
AF17121 Specificity and the Two-Site Model of
Receptor Recognition and Antagonism -We found in this work that AF17121 inhibited IL5 but not IL3 activity (see Results using TF1. 28 and BaF3 cells). The root of this specificity may reside in the nature of the IL5 binding epitopes in IL5Rα. We have previously proposed a model in which the binding interface of receptor α comprises a cluster of negatively-charged residues from D1 domain, termed as site I, and a cluster of positively-charged residues from D2D3 domains, termed as site II (Fig. 7) . We surmised that the IL5 binding epitope of IL5Rα can be divided into two components from both structural and functional points of view; site I may recognize IL5 with high specificity while site II may play a role in the conformational rearrangement of the IL5Rα to activate the common receptor βc. Intriguingly, AF17121 uses residues from both sites I and II for binding, and this peptide binding hence may take on IL5 specificity characteristics built into these sites.
In order to investigate this specificity in more depth, we performed multiple alignments of receptor α for IL5, IL3 and GM-CSF, which share similarity in amino acid sequence (Fig. 8) .
Looking at this alignment, we noticed several features about variability versus commonality. First, D1 domain is less conserved overall than D2 and D3 domains in these receptors. The sequence alignment shows 21% similarity (4% identity) in D1 domain, 44% similarity (24% identity) in D2 domain, and 40% similarity (16% identity) in D3 domain. More importantly, the positions of key IL5 binding residues in site I, all of which are in the D1 domain (Fig. 7) , are hypervariable among these three receptors (Fig.  8) . These observations suggest that site I is a primary determinant for ligand specificity. In contrast, site II shows a combination of variability (in D2) and commonality (in D3). While specificity may also be driven through this site, one of the key IL5-binding residues, Arg 297 of D3, is conserved in all three receptor α chains. This finding argues that the conserved arginine residue could be important for βc recruitment, since α receptors for IL3, IL5 and GM-CSF share the signal-transducing receptor. This speculation is favored by modeled structures of the three-component complex of IL3/IL3Rα/βc and GM-CSF/GM-CSFRα/βc, in which the conserved arginine residues of the receptor α for IL3 and GM-CSF (Arg 259 and Arg
280
, respectively) make close contacts with βc (34).
Our finding that AF17121 recognizes both site I and site II suggests that both binding sites can represent major targets for structurebased design of IL5Rα antagonists. We may surmise that targeting site I will be important to derive a specific antagonist for IL5Rα, while blocking site II offers the opportunity to interfere with IL5 biological activity induced by multisubunit receptor recruitment involving the common βc subunit (see below). This can be seen in the IL5 ligand side, as we previously found that roles of the receptor binding epitope of IL5 can be separated into receptor-recognition residues like Arg 91 and receptor-activation residues like Glu 110 (35, 36) . In this regard, considering their charge complementarity, it would be reasonable to speculate that Arg 91 and Glu 110 of IL5 are more likely to be candidates for binding partners of site I and site II on IL5Rα, respectively. Correspondingly, Arg 6 and at least a subset of the N/C-terminal acidic cluster of AF17121 might mimic these types of residues in IL5 and therein recognize site I and site II on the receptor, respectively. The distance between Arg 91 and Glu 110 in the crystal structure of IL5 is about 24 Å, which appears to be far greater than the distance between Arg 6 and the N/C-terminal acidic cluster in AF17121. Indeed, our previous modeling analysis of AF17121 has yielded a possible distance of approximately 14 Å (21). This may argue the possibility that the hinge region between D1 and D2D3 domains of IL5Rα might be flexible enough to allow conformational rearrangement of inter-domain packing that brings site I and site II closer for AF17121 binding than for IL5 binding. This explanation seems to be in good agreement with the previous data of thermodynamic and kinetics analyses that considerable conformational rearrangement could take place in IL5Rα upon IL5 binding (19, 29) .
Although AF17121, mimicking IL5, blocks not only the specific epitope (site I) but also the activating epitope (site II) on IL5Rα, no agonist activity for IL5Rα was observed (Fig. 5) as reported previously (20) . The activation of IL5 receptor depends on specific interaction of IL5 with IL5 receptor α, the formation of oligomeric receptor complexes with receptor βc, the disulfide bridge formation between receptor α and βc, and initiation of cytoplasmic phosphorylation events (37) . The lack of agonist activity of AF17121 can be surmised to originate from the inability of AF17121-IL5Rα complex to form an activated complex with receptor βc. This may be simply because AF17121 lacks a critical binding epitope for βc, such as Glu 13 in IL5 (17) , so as to be incapable of full receptor oligomerization with βc. Another possibility is that complex formation of AF17121-receptor leads to an alternative conformational state of IL5Rα that prevents effective βc recruitment. This possibility is favored by the hypothesis that IL5 and AF17121 might induce different conformational states of IL5Rα as discussed above. Since the free cysteine (Cys 66 ) in D1 domain is thought to be involved in the disulfide bond formation between receptor α and βc (37), the spatial alignment of D1 domain and D2D3 tandem domain of IL5Rα would be important for recruiting βc to the IL5-IL5Rα complex. Such an alignment could be altered by an inappropriate IL5Rα conformation stabilized by AF17121.
In summary, we have demonstrated that Asp 55 , Arg 188 and Arg 297 are the critical amino acid residues in determining receptor α recognition by AF17121 and competition for IL5. This provides a strong argument that AF17121 mimicry of IL5 plays a key role in the mechanism of receptor antagonism. The results illuminate a simplifying concept of how receptor α can recruit an activating component (IL5) and an inhibitory component (AF17121) into the same binding site, and provide a rationale for designing low molecular weight antagonists. We have proposed the notion that the IL5 binding epitope of IL5Rα can be divided into two functional sites: site I may recognize IL5 with high specificity, while site II may play a role in activating common receptor βc. We believe that this notion has a biological significance, which can be applied to other cytokine receptor systems like IL3 and GM-CSF.
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